View this email in your browser
October 2020
Donate Today
Thank you to all our 2020 Virtual Dragonslayers! This has been a challenging year but we did it. $43K total raised and still counting. You can donate through the end of 2020.

As of walk date: 

Top fundraising teams
Team Ortblad ~ $10,390
Conrad Minions ~ $5,205
Team O ~ $4,040

Largest teams
Team Jenna - 27 members!
SCCA Sarcoma - 12 members!
Team Sarcoma Sole Sisters - 11 members!

Top fundraising individuals - not on a team
Jo McNeal ~ $790
Ashley Glover ~ $420

Dragonslayer tee shirts were earned this year by fundraising a minimum of $150.00. Tee shirt order links have gone out, if you didn't recieve one but think you should have, please contact: 

Thank you again to our corporate partners: OHSU/Knight Cancer Institute, Skinny Dipped Almonds, Les Schwab Tires, Zimmer Biomet and Seattle Cancer Care Alliance.
Others ways to contribute:

AmazonSmile - If you use Amazon and you want to help support us, please choose AmazonSmile and choose the Northwest Sarcoma Foundation (or click HERE) as your charity! Below is what we have received to date from AmazonSmile and what has been given to all charities in the US. Small giving can add up.
  • $1,724.70 to Northwest Sarcoma Foundation = almost 7 Help$ Grants to patients.
  • $198,636,544.70 to all charities in the US
Sarcoma Patient Education Conference
Virtual Dinner & Show: Halloween Bingo
November 17, 2020, 7 - 8:30 p.m. Free event, register HERE.
Dr. Michael Wagner works tirelessly to make newer therapies more available to patients. He tries to match the right treatment to the right patient. Join us to learn more about how his research has been progressing.
Virtual Dinner & Show: Holiday Music
January 13, 2021, 7 - 8:30 p.m. Free event, register HERE.
Dr. Elizabeth Lawlor is a researcher at Seattle Children's and focuses on the understanding the fundamental biology of Ewing Sarcoma. She believes that better therapies and cures for childhood cancer are at our fingertips thanks to rapid advances in science and technology. You can read a little more about her via GeekWire.


With the decision of Denise Reinke earlier this year to step down from her roles as president and CEO and board chair, SARC is pleased to announce the successful recruitment of two new leaders who will step into these key positions.
Ernest “Chappie” Conrad, MD was elected SARC board chair at the board’s August meeting, and Steven Young has been selected to become SARC’s president and CEO beginning October 1, 2020.

Dr. Conrad has accepted the position of board chair, having served as a member of SARC’s board of directors since 2019. He is well known and respected within the sarcoma community as a leader in orthopaedic oncology. Since 2017, Dr. Conrad has been a professor in the Department of Orthopedic Oncology at McGovern Medical School at the University of Texas Health and Science Center in Houston. Previously, Dr. Conrad spent 30 years in Seattle where he led the sarcoma service in the department of orthopaedics at the University of Washington, as well as the pediatric orthopaedic clinic at Seattle Children’s Hospital. In 1996, he founded the Northwest Sarcoma Foundation, which remains a strong sarcoma advocacy group supporting patients, families, and researchers in the Pacific Northwest. Dr. Conrad is well positioned to provide leadership and direction to the SARC organization at this pivotal juncture. "I am very excited to assist my SARC partners with our commitment to collaboration and research on behalf of sarcoma patients and families. Moving SARC forward with new leadership will be challenging given Denise Reinke's remarkable accomplishments over the last 18 years but it is a challenge that we are all ready to accept and meet with success,” said Dr. Conrad.

Additionally, SARC is pleased to announce the recruitment, following a national search, of Steven Young to the role of president and CEO of SARC. Mr. Young brings extensive leadership experience in non-profit cancer organizations, having served as president and COO of Addario Lung Cancer Medical Institute from 2008 to 2018 and executive director of the Multiple Myeloma Research Consortium from 2003 to 2008. Most recently, Mr. Young has been engaged in independent consulting, supporting a just-announced genomics/precision medicine study in rare tumors, including sarcoma. His commitment to team science and his track record of driving patient-centric research into the clinic has Mr. Young well-positioned to guide SARC in achieving its mission of improving outcomes for patients with sarcoma. “I am honored to be entrusted with the role of president and CEO,” said Mr. Young, “and eager to help lead in close partnership with patients, investigators, and other stakeholders, SARC’s existing and new high impact research initiatives directed towards accelerating the discovery and delivery of therapeutic and diagnostic advancements to sarcoma patients in the U.S. and beyond.”

Denise Reinke will remain with SARC as past president through the end of 2020 to aid with the onboarding of SARC’s new president and CEO. Beginning in 2021, Denise will retain a role with SARC as a research manager, continuing her work on NIH-funded grants, projects, and patient advocacy. “It has been an honor to work with the SARC community and support the important work of SARC for the past 18 years. I look forward to working with Mr. Young and Dr. Conrad and continuing to support the mission of SARC in my new role,” said Denise.
Copyright © 2020 Northwest Sarcoma Foundation, All rights reserved.

You are receiving this email because you have supported or been supported by the Northwest Sarcoma Foundation. We do not sell any supporter information.
Our mailing address is:
Northwest Sarcoma Foundation
117 E. Louisa Street #443
Seattle, WA 98102

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.